{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:57:49Z","timestamp":1794023869554,"version":"4.8.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01894","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T11:27:35Z","timestamp":1598009255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":172,"title":["Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F"],"prefix":"10.3389","volume":"11","author":[{"given":"Ralph","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Maroof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair D. G.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Paveley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Rapecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Vajjah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryn","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","article-title":"Functional specialization of interleukin-17 family members","volume":"34","author":"Iwakura","year":"2011","journal-title":"Immunity."},{"key":"B2","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.4049\/jimmunol.177.1.566","article-title":"IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis","volume":"177","author":"Komiyama","year":"2006","journal-title":"J Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice","volume":"171","author":"Nakae","year":"2003","journal-title":"J Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/art.40770","article-title":"Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis","volume":"71","author":"van Tok","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding","volume":"20","author":"Hymowitz","year":"2001","journal-title":"EMBO J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/cr.2007.35","article-title":"A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses","volume":"17","author":"Chang","year":"2007","journal-title":"Cell Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"13447","DOI":"10.1074\/jbc.M700499200","article-title":"Identification of an interleukin 17F\/17A heterodimer in activated human CD4+ T cells","volume":"282","author":"Wright","year":"2007","journal-title":"J Biol Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jep.2013.06.017","article-title":"The root barks of morus alba and the flavonoid constituents inhibit airway inflammation","volume":"149","author":"Lim","year":"2013","journal-title":"J Ethnopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/eji.201948138","article-title":"Presence, function, and regulation of IL-17F-expressing CD4+ T cells","volume":"50","author":"Burns","year":"2019","journal-title":"Eur J Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cyto.2008.12.024","article-title":"IL-17F: regulation, signaling and function in inflammation","volume":"46","author":"Chang","year":"2009","journal-title":"Cytokine."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1084\/jem.20071978","article-title":"Regulation of inflammatory responses by IL-17F","volume":"205","author":"Yang","year":"2008","journal-title":"J Exp Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/ard.2010.132233","article-title":"IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes","volume":"70","author":"Hot","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.4049\/jimmunol.0801967","article-title":"Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes","volume":"182","author":"Zrioual","year":"2009","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1378\/chest.09-3058","article-title":"Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD","volume":"138","author":"Doe","year":"2010","journal-title":"Chest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/ijms17010046","article-title":"Sulfasalazine treatment suppresses the formation of HLA-B27 heavy chain homodimer in patients with ankylosing spondylitis","volume":"17","author":"Yu","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"Beta-defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science."},{"key":"B23","volume-title":"Taltz (ixekizumab) [package insert].","author":"PI","year":"2019"},{"key":"B24","volume-title":"Cosentyx (secukinumab) [package insert].","author":"PI","year":"2018"},{"key":"B25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/btpr.1693","article-title":"A CHO cell line engineered to express XBP1 and ERO1-Lalpha has increased levels of transient protein expression","volume":"29","author":"Cain","year":"2013","journal-title":"Biotechnol Prog."},{"key":"B28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jala.2009.05.004","article-title":"High-throughput screening for high affinity antibodies","volume":"14","author":"Tickle","year":"2009","journal-title":"J Assoc Lab Autom."},{"key":"B29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4161\/mabs.2.5.12833","article-title":"Properties of a general PK\/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets","volume":"2","author":"Davda","year":"2010","journal-title":"MAbs."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J Pharm Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res."},{"key":"B32","unstructured":"Cosentyx Assessment Report2014"},{"key":"B33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and\u221217F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity."},{"key":"B34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1074-7613(02)00391-6","article-title":"Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses","volume":"17","author":"Nakae","year":"2002","journal-title":"Immunity."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","article-title":"The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex","volume":"181","author":"Wright","year":"2008","journal-title":"J Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.bbrc.2007.02.042","article-title":"A broad range of Fab stabilities within a host of therapeutic IgGs","volume":"355","author":"Garber","year":"2007","journal-title":"Biochem Biophys Res Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1038\/s41598-017-03027-x","article-title":"Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity","volume":"7","author":"Sagar","year":"2017","journal-title":"Sci Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomised study of bimekizumab, a humanised monoclonal antibody and selective dual inhibitor of IL-17A and IL-17 F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled Phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2019-eular.4883","article-title":"Dual neutralization of IL-17A and IL-17F with bimekizumab in patients with active PsA: results from a 48-week phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"70","author":"Ritchlin","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"A70","DOI":"10.1136\/annrheumdis-2018-eular.7889","article-title":"Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"77","author":"Van der Heijde","year":"2018","journal-title":"Ann Rheum Dis."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:28:51Z","timestamp":1696552131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2020.01894"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01894","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"article-number":"1894"}}